Abstracts tagged "complement"

Abstract Number: 1751 • 2016 ACR/ARHP Annual Meeting
Coagulation Pathway Function in Ischemia/Reperfusion Tissue Injury in Autoimmune Prone Mice
Rachel C. Robbins¹, Christopher Tracy², Jess Edison¹, Suzette Peng³ and Chantal Moratz⁴, ¹Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ²Walter Reed National Military Medical Center, Bethesda, MD, ³Food and Drug Administration, Silver Spring, MD, ⁴Uniformed Services University, Bethesda, MD
Results: Tissue Factor Pathway Inhibitor (TFPI) and Anti-thrombin III (ATIII) resulted in reduction of tissue injury, as determined by histopathology scoring. However, TFPI was significantly…
Abstract Number: 2421 • 2016 ACR/ARHP Annual Meeting
Cell-Bound Complement Activation Products Correlate with Disease Activity in Childhood-Onset Systemic Lupus Erythematosus
Joyce Hui-Yuen¹, Derren Barken², John Conklin³, Tyler O'Malley⁴, Andrew Eichenfield⁵, Amy Starr⁶, Lisa F. Imundo⁷, Thierry Dervieux⁸ and Anca D. Askanase⁹, ¹North Shore-Long Island Jewish Health System, Lake Success, NY, ²Exagen Diagnostics, Inc., Vista, CA, ³1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁴Research and Development, Exagen Diagnostics, Vista, CA, ⁵Morgan Stanley Children's Hospital of NY-Presbyterian, Columbia University, New York, NY, ⁶Pediatric Rheumatology, Columbia University Medical Center, New York, NY, ⁷Assoociate Professor of Pediatrics in Medicine - Rheumatology, Columbia University Medical Center, New York, NY, ⁸Research and Development, Exagen Diagnostics, Inc., Vista, CA, ⁹Department of Medicine, Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Elevated levels of cell-bound complement activation products (C4d deposition on erythrocytes [EC4d] and B lymphocytes [BC4d], CB-CAPs) have been demonstrated to be sensitive and…
Abstract Number: 2797 • 2016 ACR/ARHP Annual Meeting
Prospective Validation of a Panel of Autoantibodies in Combination with C4d-Bound Complement Activation Products for the Differential Diagnosis of Systemic Lupus Erythematosus
Daniel J Wallace¹, Rosalind Ramsey-Goldman², Anca D. Askanase³, Susan Manzi⁴, Joseph Ahearn⁵, Richard Furie⁶, Arthur Weinstein⁷, Chaim Putterman⁸, Elena Massarotti⁹, Christopher Collins¹⁰, Kenneth Kalunian¹¹, Cristina Arriens¹², Stuart L. Silverman¹³, Smitha Reddy¹⁴, Puja Chitkara¹⁵, Claudia Ibarra¹⁶, Derren Barken¹⁷, Roberta Alexander¹⁸, John Conklin¹⁹ and Thierry Dervieux²⁰, ¹Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ²FSM, Northwestern University, Chicago, IL, ³Medicine, Rheumatology, Columbia University Medical Center, New York, NY, ⁴Lupus Center of Excellence, West Penn Allegheny Health System, Pittsburgh, PA, ⁵Allegheny Singer Research Institute, Allegheny Health Network, Pittsburgh, PA, ⁶North Shore University Hospital, Great Neck, NY, ⁷Rheumatology Section, Washington Hospital Center, Washington, DC, ⁸Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ⁹Rheumatology, Immunology, & Allergy, Harvard Medical School, Brigham & Women's Hosp, Boston, MA, ¹⁰MedStar Washington Hospital Center, Washington, DC, ¹¹Center for Innovative Therapy, UCSD School of Medicine, La Jolla, CA, ¹²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹³Cedars, Beverly Hills, CA, ¹⁴Arthritis Care and Research Center, Inc., Poway, CA, ¹⁵Rheumatology, Center For Arthritis and Rheumatologic Excellence, Chula Vista, CA, ¹⁶Clinical Laboratory, Exagen Diagnostics, Vista, CA, ¹⁷Exagen Diagnostics, Vista, CA, ¹⁸Research & Development, Exagen Diagnostics, Vista, CA, ¹⁹1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ²⁰Research and Development, Exagen Diagnostics, Vista, CA
Background/Purpose: A panel of autoantibodies in combination with C4d-bound complement activation products (CB-CAPs, EC4d and BC4d) has been established as a sensitive and specific testing…
Abstract Number: 2856 • 2016 ACR/ARHP Annual Meeting
Serum C5a Is Elevated in Lupus Nephritis and in Neuropsychiatric Systemic Lupus Erythematosus through Different Mechanisms
Yuko Sakuma¹, Tatsuo Nagai², Taku Yoshio³ and Shunsei Hirohata⁴, ¹Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, ²Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan, ³Jichi Medical University, Tochigi, Japan, ⁴Kitasato University School of Medicine, Sagamihara, Japan
Background/Purpose: Neuropsychiatric manifestation in systemic lupus erythematosus (NPSLE) is one of the most serious complications of the disease. We have recently demonstrated that the breakdown…
Abstract Number: 198 • 2015 ACR/ARHP Annual Meeting
CL-L1 and CL-K1 Complement Associated Pattern Recognition Molecules in Systemic Lupus Erythematosus
Anne Troldborg¹, Steffen Thiel², Lisbeth Jensen³, Magdalena Janina Laska², Søren Hansen⁴, Bent Deleuran^5,6, Jens Christian Jensenius² and Kristian Stengaard-Pedersen⁵, ¹clinical medicine, Aarhus University, Aarhus, Denmark, ²Biomedicine, Aarhus University, Aarhus, Denmark, ³Biomedicin, Aarhus University, Aarhus, Denmark, ⁴Department of cancer and inflammation research, University of Southern Denmark, Odense, Denmark, ⁵Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁶Biomedicin, Aarhus University, 8000, Denmark
Background/Purpose: The complement system is one of the key players in the pathogenesis of systemic lupus erythematosus (SLE). Collectin liver 1 (CL-L1) and collectin kidney…
Abstract Number: 519 • 2015 ACR/ARHP Annual Meeting
In Indigenous North Americans at High Risk for RA Complement C5 Level Is Associated with ACPA Positivity and C5a with Transition to Synovitis Even after Correcting for in Vitro Complement Activation Found with Prolonged Sample Storage
Ceri Richards¹, Carol Hitchon², Xiaobo Meng³, Irene Smolik⁴, David Robinson⁴ and Hani S. El-Gabalawy⁴, ¹Internal Medicine, University of Manitoba, Winnipeg, MB, Canada, ²Department of Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ³University of Manitoba, Winnipeg, MB, Canada, ⁴Arthritis Center, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Complement activation, a key component of innate immunity and activator of adaptive immunity has been linked to RA pathogenesis. Anti-citrullinated peptide antibody (ACPA) and…
Abstract Number: 772 • 2015 ACR/ARHP Annual Meeting
Post-Phlebotomy Stability of Soluble and Cellular Forms of Complement Activation: Implications in SLE Diagnostic Assays
John Conklin¹, Basil Jones², Tyler O'Malley³, Duncan Poling⁴, JoAnne Ligayon⁵, Leilani Wolover⁶, Ying Qu⁷, Claudia Ibarra⁸, Puja Chitkara⁹ and Thierry Dervieux³, ¹1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ²Exagen Diagnostics, Vista, CA, ³Research and Development, Exagen Diagnostics, Vista, CA, ⁴Research and Development, Exagen Diagnostics Inc., Vista, CA, ⁵Flow Cytometry, Exagen Diagnostics Inc., Vista, CA, ⁶Research and Development, Exagen Diagnostics, Inc., Vista, CA, ⁷Exagen Diagnostic Inc, Vista, CA, ⁸Clinical Laboratory, Exagen Diagnostics, Vista, CA, ⁹Rheumatology, Center For Arthritis and Rheumatologic Excellence, Chula Vista, CA
Background/Purpose: Deregulation and activation of the classical complement system is known to be associated with systemic lupus erythematosus (SLE). As such, several investigators have proposed…
Abstract Number: 819 • 2015 ACR/ARHP Annual Meeting
Upregulation of Complement C3 and Alpha-2-Macroglobulin in Cerebrospinal Fluid of Neuropsychiatric Systemic Lupus Erythematosus
Tomoyuki Asano¹, Shuzo Sato¹, Hiroko Kobayashi¹, Yoshinobu Kariya², Hiromi Ito², Kyoka Hoshi², Akioh Yoshihara³, Yoshikazu Ugawa³, Minoru Takahashi⁴, Hideharu Sekine⁴, Shunsei Hirohata⁵, Hiroshi Watanabe¹, Hiromasa Ohira¹ and Yasuhiro Hashimoto², ¹Gastroenterology and Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan, ²Biochemistry, Fukushima Medical University School of Medicine, Fukushima, Japan, ³Neurology, Fukushima Medical University School of Medicine, Fukushima, Japan, ⁴Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan, ⁵Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan
Background/Purpose: Various autoantibodies have been identified in cerebrospinal fluids (CSF) of neuropsychiatric systemic lupus erythematosus (NPSLE). They are supposed to form immune complex with complement…
Abstract Number: 1996 • 2015 ACR/ARHP Annual Meeting
Complement Activation Predicts Adverse Pregnancy Outcome in Patients with SLE and/or aPL Antibodies
Jane E. Salmon^1,2, Mimi Kim³, Marta Guerra⁴, Elianna Kaplowitz¹, Carl Laskin⁵, Michelle Petri⁶, Ware D. Branch^7,8, Michael Lockshin⁹, Lisa R. Sammaritano², Joan T. Merrill¹⁰, Mary D. Stephenson¹¹, Munther Khamashta¹², Alan M. Peaceman¹³, Anne Lynch¹⁴ and Jill P. Buyon¹⁵, ¹Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Biostatistics and Research Design Resource, Albert Einstein Coll Med, Bronx, NY, ⁴Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, ⁵Medicine, Rheumatology and Obstetrics and Gynecology, University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, Canada, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷University of Utah, Salt Lake City, UT, ⁸Intermountain Healthcare, Salt Lake City, UT, ⁹Barbara Volcker Center for Women & Rheumatic Disease, Hospital for Special Surgery, New York, NY, ¹⁰Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹University of Illinois College of Medicine, Chicago, IL, ¹²Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ¹³Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁴Colorado School of Public Health, Aurora, CO, ¹⁵NYU School of Medicine, New York, NY
Background/Purpose: Women with SLE and/or aPL antibodies (SLE/APL) are at increased risk for adverse pregnancy outcomes (APO) yet identification of those destined for complications remains…
Abstract Number: 2043 • 2015 ACR/ARHP Annual Meeting
Cell-Bound Complement Activation Products Have High Sensitivity and Specificity in Childhood-Onset Systemic Lupus Erythematosus and Juvenile Idiopathic Arthritis
Anca Askanase¹, Joyce Hui-Yuen², John Conklin³, Derren Barken⁴, Tyler O'Malley⁵, Xiao Qing Li⁶, Liza Mariel Bermudez², Andrew Eichenfield⁷, Amy J. Starr⁸, Lisa F. Imundo^9,10 and Thierry Dervieux¹¹, ¹Columbia University College of Physicians & Surgeons, New York, NY, ²Pediatric Rheumatology, Columbia University Medical Center, New York, NY, ³1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁴Exagen Diagnostics, Inc., Vista, CA, ⁵Research and Development, Exagen Diagnostics, Vista, CA, ⁶Adult Rheumatology, Columbia University Medical Center, New York, NY, ⁷Morgan Stanley Children's Hospital of NY-Presbyterian, Columbia University, New York, NY, ⁸Columbia University Medical Center, New York, NY, ⁹Assoociate Professor of Pediatrics in Medicine - Rheumatology, Columbia University Medical Center, New York, NY, ¹⁰New York Presbyterian Hospitsl, Columbia University, New York, NY, ¹¹Research and Development, Exagen Diagnostics, Inc., Vista, CA
Background/Purpose: Elevated levels of cell-bound complement activation products (C4d deposition on erythrocytes [EC4d] and B lymphocytes [BC4d], CBCAPS) have been demonstrated to be sensitive and…
Abstract Number: 2120 • 2015 ACR/ARHP Annual Meeting
Alterations in Complement C3 and iC3b in SLE Pregnancies
Marta M. Guerra¹, Martin Schmidt², Elianna Kaplowitz³, Vibeke Strand⁴ and Jane E. Salmon⁵, ¹Rheumatology 3rd Fl Rsrch, Hospital for Special Surgery, New York, NY, ²Kypha, Inc., St. Louis, MO, ³Hospital for Special Surgery, New York, NY, ⁴Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, CA, ⁵Division of Rheumatology, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Pregnancy in patients with SLE is associated with increased risk of maternal and fetal complications. Studies in experimental models and humans suggest that complement…
Abstract Number: 2180 • 2015 ACR/ARHP Annual Meeting
Primary Antiphospholipid Syndrome Patients Display Increased Levels of Cell-Bound C4d in Comparison to SLE and Healthy Donors
Maria Gerosa^1,2, Paola Adele Lonati³, Tania Ubiali¹, Martina Cornalba¹, Maria Orietta Borghi^1,4 and Pier Luigi Meroni^1,2,5, ¹Department of Clinical Sciences and Community Health, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ²Division of Rheumatology, Division of Rheumatology, Istituto Ortopedico Gaetano Pini, Milan, Italy, ³Laboratory of Immuno-rheumatology, Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Cusano Milanino, Jamaica, ⁴Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁵Laboratory of Immuno-rheumatology, Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Cusano Milanino, Italy
Background/Purpose: Systemic Lupus Erythematosus (SLE) patients display high levels of the cell-bound complement activation factor C4d deposits on erythrocytes, B lymphocytes and platelets. In particular,…
Abstract Number: 938 • 2014 ACR/ARHP Annual Meeting
C1q Is Mandatory for Disease Development in Experimental Arthritis and Expression of Its Receptors Correlates with Disease Activity in Patients
Matthieu Ribon¹, Julie Mussard¹, Roxane Herve¹, Marina Botto², Marie-Christophe Boissier³ and Patrice Decker¹, ¹INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité and Rheumatology Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France, ²Centre for Complement & Inflammation Research, Imperial College, London, United Kingdom, ³INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité, Bobigny, France
Background/Purpose The complement system is a major effector mechanism of innate and adaptive immunity. It is activated in rheumatoid arthritis (RA) patients but the pathway…
Abstract Number: 2844 • 2014 ACR/ARHP Annual Meeting
Intracellular Complement C3 Is Exposed on the Cell Surface upon Apoptosis Induction and Participates in the Clearance of Apoptotic Cells By Phagocytes
Lucrezia Colonna¹, Christian Lood¹, YuFeng Peng², Xizhang Sun³, Lena Tanaka³, Sandip Panicker⁴ and Keith B. Elkon³, ¹Department of Medicine, Division of Rheumatology, University of Washington, Seattle, WA, ²Rheumatology, University of Washington, Seattle, WA, ³Division of Rheumatology, University of Washington, Seattle, WA, ⁴True North Therapeutics, South San Francisco, CA
Background/Purpose The complement system has been viewed as a predominantly serum-derived host defense mechanism with multiple functions, including clearance of apoptotic cells. Defective function of…
Abstract Number: 2299 • 2014 ACR/ARHP Annual Meeting
M-Ficolin and Masp-2 As Inflammatory Markers in Oligoarticular and Systemic Juvenile Idiopathic Arthritis
Christine Petri¹, Steffen Thiel², Jens Christian Jensenius² and Troels Herlin¹, ¹Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ²Biomedicine, Aarhus University, Aarhus, Denmark
Background/Purpose The lectin pathway of the complement plays a crucial role in the pathogenesis of various inflammatory processes. The lectin pathway proteins are activated through…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].